Expect Biocon Biologics to become a fully integrated global biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw

Biocon's Chairperson Kiran Mazumdar-Shaw in a QnA with FE’s Srinath Srinivasan, talks about the bold moves Biocon Biologics is making since 2021, including the recent acquisition of Viatris’ global biosimilars business, which will provide it a direct entry into the US & Europe with the acquired commercial engine in developed and key emerging markets. This … Continue reading Expect Biocon Biologics to become a fully integrated global biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw

The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw

Biocon Biologics on Monday announced a transformational deal to acquire partner Viatris’ global biosimilars business for up to USD 3.335 billion in cash and stock. The acquisition of the business, which is estimated to generate revenues of USD 1 billion next year, will create a unique, fully integrated global biosimilars enterprise. Kiran Mazumdar-Shaw, Executive Chairperson, … Continue reading The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw

Biocon developing 20 biosimilar products for global markets

India's premier biopharmaceutical company Biocon is working on a pipeline of 20 biosimilar drugs or similar but not identical copy of biologic medicines, to tap the upcoming huge opportunity. Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products. It has biosimilars in oncology like … Continue reading Biocon developing 20 biosimilar products for global markets

‘Our Alliance with Serum Institute Provides an Accelerated Entry into Vaccines’

Dr Arun Chandavarkar, Managing Director, Biocon Biologics Ltd., says the structure of the strategic alliance with Serum Institute Life Sciences provides Biocon Biologics with an asset light and accelerated entry into the often overlooked infectious diseases segment. Having established capabilities and a track record of success in biologics, Biocon Biologics’ foray into vaccines and antibodies for … Continue reading ‘Our Alliance with Serum Institute Provides an Accelerated Entry into Vaccines’

A Unique & Synergistic Alliance to Impact Global Health

Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd, have entered into a historic alliance to impact global health. This alliance will complement the strengths and resources of two leading Indian players in addressing inequitable access both in … Continue reading A Unique & Synergistic Alliance to Impact Global Health

Biosimilars Regulatory Framework Must Evolve in Line with Emerging Scientific Evidence

Dr. Sundar Ramanan, Global Head of Regulatory Affairs, Biocon Biologics Dr. Sundar Ramanan, Vice President & Head, Global Regulatory Affairs, Biocon Biologics, presented on behalf of the Company at the public meeting for the reauthorization process for the Biosimilar User Fee Act (BsUFA III) program organized by the U.S. Food and Drug Administration (FDA) on … Continue reading Biosimilars Regulatory Framework Must Evolve in Line with Emerging Scientific Evidence

Early Insulinization Can be Key to Effective Diabetes Management

Diabetes is a global epidemic and the number of people with diabetes globally is growing at an alarming rate. An estimated 463 million adults (20-79 years), or about 1 in 11 adults worldwide, are living with diabetes across the world in 2019; by 2045 this will rise to 700 million1. Globally, the number of people … Continue reading Early Insulinization Can be Key to Effective Diabetes Management

A Disease of Halves: Why better patient adherence to treatment is important to manage diabetes?  

Diabetes Mellitus is a major health issue with nearly half a billion people living with this ailment globally. Diabetes is a serious, chronic or long-term condition that occurs when there are elevated levels of glucose in a person’s blood because their body cannot produce any or enough of the hormone insulin, or cannot effectively use … Continue reading A Disease of Halves: Why better patient adherence to treatment is important to manage diabetes?  

Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents/Day for LMICs

Kiran Mazumdar Shaw speaks at the UNAIDS Health Innovation Exchange Meeting on the sidelines of United Nations General Assembly, held in New York on 25th September 2019. Your Excellencies, Distinguished Ladies and Gentlemen, We have just witnessed the first UN High Level meeting on Universal Health Care on Monday. Governments have a collective moral responsibility … Continue reading Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents/Day for LMICs

US-India Leaders Summit: Paving the Way for Affordable Diabetes & Cancer Care in the US

India and the U.S. are witnessing a deepening of ties with a convergence of views on many issues. India is rapidly emerging as a preferred economic and technology partner for the US. India IT and pharma companies have made significant investments and have created jobs in the US. These investments signal a growing economic interdependence … Continue reading US-India Leaders Summit: Paving the Way for Affordable Diabetes & Cancer Care in the US